VERV Overview
Upcoming Projects (VERV)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (VERV)
-
Third View: Discussing Verve Therapeutics' Phase1B results for VERVE-102, an in vivo base editing medicine targeting PCSK9.
Ticker: VERV
Executed On: May 02, 2025 at 10:00 AM EDT -
Second View: Discussing Verve Therapeutics' Phase1B results for VERVE-102, an in vivo base editing medicine targeting PCSK9.
Ticker: VERV
Executed On: May 01, 2025 at 09:30 AM EDT -
Discussing Verve Therapeutics' Phase1B results for VERVE-102, an in vivo base editing medicine targeting PCSK9.
Ticker: VERV
Executed On: Apr 24, 2025 at 05:00 PM EDT -
A Third Look: Discussing the recent interim results from the heart-1 clinical trial of VERVE-101 in patients with heterozygous familial hypercholesterolemia.
Tickers: VERV, NVS
Executed On: Nov 22, 2023 at 05:05 PM EST -
A Second Look: Discussing the recent interim results from the heart-1 clinical trial of VERVE-101 in patients with heterozygous familial hypercholesterolemia.
Tickers: VERV, NVS
Executed On: Nov 20, 2023 at 11:00 AM EST -
Discussing the recent interim results from the heart-1 clinical trial of VERVE-101 in patients with heterozygous familial hypercholesterolemia.
Tickers: VERV, NVS
Executed On: Nov 17, 2023 at 12:35 PM EST
Upcoming & Overdue Catalysts (VERV)
-
Don’t see a catalyst related to the company you care about? Create your own!
Strategic Initiatives (VERV)
-
Don’t see a strategic initiative related to the company you care about? Create your own!
